No Data
No Data
Wuhan Hiteck Biological Pharma (300683.SZ): Obtains the pharmaceutical registration certificate for injectable esomeprazole sodium.
On September 11, Gelonghui reported that Wuhan Hiteck Biological Pharma (300683.SZ) announced that the company recently received the "Drug Registration Certificate" for injection of esomeprazole sodium issued by the National Medical Products Administration. Esomeprazole, also known as esomeprazole, is the single left-handed isomer of omeprazole. Both belong to proton pump inhibitors, which can effectively inhibit the secretion of gastric acid, and are clinically used to treat gastroesophageal reflux disease, erosive esophagitis, etc. This drug is one of the most successful examples of isomer development. Compared with the first generation omeprazole, it has a stronger effect in inhibiting gastric acid and fewer adverse reactions. This drug was originally developed by AstraZeneca.
Haite Biotech: 2024 Semi-Annual Report Summary
Haite Biotech: 2024 Semi-Annual Report
wuhan hiteck biological pharma (300683.SZ): a net loss of 227.656 million yuan in the first half of the year, with an expanded year-on-year loss.
Gelonghui, August 26th, Wuhan Hiteck Biological Pharma (300683.SZ) released the semi-annual report for 2024, with a reported half-year revenue of 0.285 billion yuan, a 0.64% decrease year-on-year; a net loss of 22.7656 million yuan attributable to the shareholders of the listed company, the loss expanded year-on-year; the net profit excluding non-recurring gains and losses attributable to the shareholders of the listed company was -47.0363 million yuan; basic earnings per share was -0.17 yuan.
As of August 9th, wuhan hiteck biological pharma (300683.SZ) had a total of 11,568 shareholders.
On August 16, Gelunhui reported that Wuhan Hiteck Biological Pharma (300683.SZ) stated on the investor interaction platform that as of August 9, the number of shareholders in the company was 11,568.
As of July 10th, the number of shareholders of Wuhan Hiteck Biological Pharma (300683.SZ) was 11,374.
On July 16th, Gelunhui reported that as of July 10th, Wuhan Hiteck Biological Pharma (300683.SZ) had 11,374 shareholders on the investor interactive platform.
No Data
No Data